Bank of America
KZR

Bank of America’s Kezar Life Sciences KZR Stock Holding History

Bank of America’s Portfolio KZR Stock Details KZR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-7,850
Closed -$1.31M – 8523
2021
Q4 		$1.31M Buy
+7,850
New +$886K ﹤0.01% 4985

Other funds holding KZR

BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RC
Rangeley Capital New Canaan, Connecticut $103M AUM 77.36% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return

Bank of America's KZR Position: Q1 2026 in Review

Bank of America sold out of Kezar Life Sciences (KZR) in Q1 2026, closing a stake of 122 shares — an estimated $768 sold.

Bank of America first reported a position in KZR in Q3 2018 and held it in 30 quarters. The position peaked at $2.48M in Q4 2021. 43 funds tracked by Wall St. Rank hold KZR as of Q1 2026.

  • Bank of America reported no remaining Kezar Life Sciences position as of Q1 2026 after selling out during the quarter.
  • Bank of America sold 122 Kezar Life Sciences shares in Q1 2026, an estimated $768.
  • Bank of America first reported a position in Kezar Life Sciences in Q3 2018 and held it in 30 quarters.
  • Bank of America's Kezar Life Sciences position peaked at $2.48M in Q4 2021.
  • 43 funds tracked by Wall St. Rank held Kezar Life Sciences as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.